Lung Cancer Clinical Trial
Official title:
An Open-label, Phase Ib, Dose-escalation Trial on the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Biological Effects and Antitumor Activity of EMD 521873 in Combination With Local Irradiation (20 Gy) of Primary Tumors or Metastases in Subjects With Non-small Cell Lung Cancer Stage IIIb With Malignant Pleural Effusion or Stage IV With Disease Control (Partial Response or Stable Disease) After Application of 4 Cycles of Platinum-based, First-line Chemotherapy
Primary trial objective in this single arm trial is to assess the safety and tolerability of
Selectikine (EMD 521873) given in combination with and local tumor irradiation and to
determine whether the maximum tolerated dose (MTD) is reached with EMD 521873 doses of up to
0.45 mg/kg.
Secondary objectives are to evaluate PK, immunogenicity, overall response, changes in tumor
marker levels and circulating tumor cell numbers, progression-free survival and overall
survival. Also, to evaluate biological/immune responses to EMD 521873.
NSCLC patients have to be stable (PR or SD) after first-line chemotherapy in order to be
enrolled. A total of 12 to 24 patients are planned. Patients will remain on the dose
throughout the trial. It is intended to administer at least 4 cycles (21 d each), or until
progression or 2nd line therapy becomes necessary.
Status | Completed |
Enrollment | 15 |
Est. completion date | September 2012 |
Est. primary completion date | February 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Histologically or cytologically confirmed NSCLC stage IIIb with malignant pleural effusion or stage IV - Pulmonary primary tumor or at least one NSCLC metastasis in the lung measuring at least 1 cm in diameter and eligible for local radiation with 20 Gy - Disease control (partial remission or stable disease) after 4 cycles of platinum-based first-line chemotherapy whereby the time between the last dose of first-line chemotherapy and start of trial treatment should not be longer than 8 weeks - Male or female, aged =18 years of age - Signed written informed consent - Effective contraception for male and female subjects of childbearing age - ECOG performance status 0 or 1 - Adequate hematological function defined by WBC =3 x 10^9/L, neutrophils =1.5 x 10^9/L, lymphocyte count =0.5 x 10^9/L, platelet count =100 x 10^9/L; hemoglobin =9 g/dL - Estimated creatinine clearance =50 mL/min according to the Cockcroft - Gault formula or 24-h urine sampling - Adequate hepatic function defined by a total bilirubin level =1.5 times the upper limit of normal (ULN), and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =5 x ULN Exclusion Criteria: - Requirement for immunosuppressive treatment with the exception of inhalative corticosteroids or low-dose systemic corticosteroids (prednisone equivalent dose =10 mg/day) - Systemic autoimmune disease (e.g. lupus erythematodes, rheumatoid arthritis) - Organ transplant recipients - Active infections (including HIV, hepatitis B and C, tuberculosis) - Known or clinically suspected brain metastases - Active cardiovascular/cerebrovascular disease (e.g. symptomatic coronary vascular disease, congestive heart failure = NYHA II, LVEF <50%, ventricular arrhythmia requiring medication, myocardial infarction or stroke) within previous 6 months - Pericardial effusion - Major impairment in pulmonary function: forced expir¬atory volume in 1 second (FEV1) <50% and diffusion capacity for carbon monoxide (DLCO) <50% of normal limit - Any other significant disease that in the Investigator's opinion would exclude the subject from the trial - Known conditions associated with necroses of non-tumor bearing tissues (e.g. esophageal or gastroduodenal ulcers, ischemic bowel disease, chronic inflammations) - Pregnancy or lactation - Radiotherapy, chemotherapy, major surgery, biological therapy or any investigational drug within 30 days prior to the start of trial treatment - Requirement for concurrent systemic anticancer treatment (chemotherapy, biological therapy) - Pretreatment with anti-EGFR antibodies or tyrosine kinase inhibitors - Participation in another interventional clinical trial within the past 30 days before start of trial treatment - Known alcohol or drug abuse - Any psychiatric condition that would prohibit the understanding or rendering of the informed consent - Legal incapacity or limited legal capacity |
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Netherlands | Department of Thoracic Oncology, Netherlands Cancer Instiute - Antoni van Leeuwenhoek Hospital | Amsterdam | |
Netherlands | Department of Pulmonology, Academic Hosptial Maastricht | Masstricht | |
Netherlands | Department of Medical Oncology (452), Radboud UMC Nijmegen | Nijmegen |
Lead Sponsor | Collaborator |
---|---|
Merck KGaA |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To assess the safety and tolerability of EMD 521873 given in combination with local irradiation of pulmonary primary tumor/metastases and to determine whether the maximum tolerated dose (MTD) is reached with EMD 521873 doses of up to 0.45 mg/kg. | Incidence of DLTs occurring during the first cycle (21 days) of administration of any dose of EMD 521873 following radiotherapy | Yes | |
Secondary | Evaluate the pharmacokinetics (PK) of EMD 521873 in combination with local tumor irradiation | First 4 cycles of treatment | No | |
Secondary | Evaluate the immunogenicity of EMD 521873 in combination with local tumor irradiation by measuring the induction of anti-EMD 521873 antibodies | First 4 cycles of treatment in each cycle, then every 4 cycles | No | |
Secondary | Collect evidence of best overall response, changes in tumor marker levels and circulating tumor cell numbers after treatment with EMD 521873 in combination with local tumor irradiation | First 4 cycles of treatment | No | |
Secondary | Collect evidence of best overall response after second-line therapy and duration of the response when it is shown | At one year of follow up | No | |
Secondary | Evaluate progression-free survival and overall survival | At one year of follow up | No | |
Secondary | Evaluate biological/immune responses following treatment with EMD 521873 by assessing changes in relevant parameters including leukocyte subset analysis | First 4 cycles of treatment | No | |
Secondary | Evaluate biological/immune responses following treatment with EMD 521873 by assessing changes in relevant parameters including: molecular markers of immune activation (e.g. cytokines/chemokines, IL-2 receptor and neopterin) | First 4 cycles of treatment | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|